Regenxbio Inc (NASDAQ:RGNX)
| 22.57 Delayed Data As of Oct 04 |  -1.57 / -6.50%Today’s Change | 18.69 Today|||52-Week Range 40.59 | -30.98% Year-to-Date |
Latest RGNX News | Press Releases
No recent news for Regenxbio Inc.
Today’s Trading
| Previous close | 24.17 |
| Today’s open | 24.33 |
| Day’s range | 22.16 - 26.32 |
| Volume | 801,373 |
| Average volume (3 months) | 391,314 |
| Market cap | $1.1B |
Data as of 4:00pm ET, 10/04/2022
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -288.98% |
| Earnings growth (next 5 years) | +11.81% |
| Revenue growth (last year) | +204.30% |
| P/E ratio | 10.7 |
| Price/Sales | 3.05 |
| Price/Book | 1.48 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AUPHAurinia Pharmaceutic... | +0.10 | +1.35% |
| EBSEmergent BioSolution... | +0.05 | +0.23% |
| RCKTRocket Pharmaceutica... | +1.72 | +11.10% |
| IMGNImmunoGen Inc | +0.51 | +10.52% |
Data as of 4:00pm ET, 10/04/2022
Financials
| Next reporting date | November 9, 2022 |
| EPS forecast (this quarter) | -$1.47 |
| Annual revenue (last year) | $470.3M |
| Annual profit (last year) | $127.8M |
| Net profit margin | 27.18% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Rockville, Maryland |
Forecasts
